NCT03561532 (FMT-CU) is a NA clinical trial of Fecal microbiota transplantation (FMT) in Ulcerative Colitis, sponsored by Joint Authority for Päijät-Häme Social and Health Care.

Who is sponsoring NCT03561532?

NCT03561532 is sponsored by Joint Authority for Päijät-Häme Social and Health Care.

What drugs are being tested in NCT03561532?

Interventions in NCT03561532: Fecal microbiota transplantation (FMT), Placebo.

What condition does NCT03561532 study?

NCT03561532 studies Ulcerative Colitis.

Is NCT03561532 still recruiting?

NCT03561532 is currently status unknown. Last updated 15 August 2019.

Last reviewed 2019-08-15 · How we verify

NCT03561532: FMT-CU

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fecal Transplantation in Ulcerative Colitis

Status unknown NA Last updated 15 August 2019

What this trial tests

NA trial testing Fecal microbiota transplantation (FMT) in Ulcerative Colitis in 48 participants. Status unknown.

Timeline

1 October 2016

Primary endpoint
31 May 2020

31 May 2020

Quick facts

Lead sponsor	Joint Authority for Päijät-Häme Social and Health Care
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	48
Start date	1 October 2016
Primary completion	31 May 2020
Estimated completion	31 May 2020
Sites	2 locations across Finland

Drugs / interventions tested

Fecal microbiota transplantation (FMT) — full drug profile →
Placebo

Conditions studied

Ulcerative Colitis — all drugs for Ulcerative Colitis →

Sponsor

Joint Authority for Päijät-Häme Social and Health Care — full company profile →

Who can join

Adults 18 to 75, any sex, with Ulcerative Colitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Adult individuals with ulcerative colitis in remission are given a single fecal microbiota transplantation (FMT) in colonoscopy. A half of the patients will receive autologous FMT as a placebo and a half will receive an FMT from a healthy donor.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Microbial-Based and Microbial-Targeted Therapies for Inflammatory Bowel Diseases.
Oka A, Sartor RB. · · 2020 · cited 126× · PMID 32006212 · DOI 10.1007/s10620-020-06090-z
Fecal microbiota transplantation beyond Clostridioides difficile infections.
Wortelboer K, Nieuwdorp M, Herrema H. · · 2019 · cited 111× · PMID 31201141 · DOI 10.1016/j.ebiom.2019.05.066
Fecal transplantation for treatment of inflammatory bowel disease.
Imdad A, Pandit NG, Zaman M, Minkoff NZ, et al · · 2023 · cited 51× · PMID 37094824 · DOI 10.1002/14651858.cd012774.pub3
Fecal microbiota transplantation for the maintenance of remission in patients with ulcerative colitis: A randomized controlled trial.
Lahtinen P, Jalanka J, Mattila E, Tillonen J, et al · · 2023 · cited 32× · PMID 37213403 · DOI 10.3748/wjg.v29.i17.2666
Ulcerative Colitis: Advances in Pathogenesis, Biomarkers, and Therapeutic Strategies.
Bu S, Cheng X, Chen M, Yu Y. · · 2025 · cited 1× · PMID 40937422 · DOI 10.2147/pgpm.s536459
Effectiveness and safety of non-pharmacological therapies for the treatment of inflammatory bowel disease: a network meta-analysis.
Jia J, Wu YB, Liu SW, Chen WJ, et al · · 2025 · PMID 40662074 · DOI 10.3389/fmed.2025.1593483

Verify or expand the search:

Other trials of Fecal microbiota transplantation (FMT)

Trials testing the same drug.

NCT07364617 — Fecal Microbiota Transplantation for Steroid-Refractory Acute GI GVHD · Phase 2 · not yet recruiting
NCT07276100 — Fecal Microbiota Transplantation to RESCUE Patients With Unresectable Hcc Progressors to First Line Therapy With Atezoli · Phase 2 · recruiting
NCT07319364 — A Real-World Study of Fecal Transplants for Cancer Therapy Side Effects · Phase 1 · recruiting
NCT07003438 — Study on the Efficacy and Safety of Fecal Microbiota Transplantation in the Treatment of Steroid - Dependent /Steroid-re · EARLY_PHASE1 · not yet recruiting
NCT06992453 — Multi-omics Dissection of Gut Microbiome Engraftment During FMT · NA · not yet recruiting

Other recruiting trials for Ulcerative Colitis

Currently open trials in the same condition.

NCT07185009 — A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Acti · Phase 3 · recruiting
NCT07265570 — Study Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA) · Phase 2 · recruiting
NCT07223424 — Patient Preference for Subcutaneous vs. Intravenous Immune Therapy · Phase 2 · recruiting
NCT06405087 — A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD · Phase 3 · recruiting
NCT07184996 — An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Activ · Phase 3 · recruiting

Other Joint Authority for Päijät-Häme Social and Health Care trials

Trials by the same sponsor.

NCT06633146 — Stroke Rehabilitation Utilizing Therapeutical Methods Designed for Nature Environments · NA · recruiting
NCT05898542 — Nature-based Therapies in Stroke Rehabilitation · NA · recruiting
NCT05005117 — Laparoscopic Approach for Emergency Colon Resection · NA · recruiting
NCT04564105 — Simulation Training and Teamwork Concerning Intubation on the Icu · NA · completed
NCT05025319 — Optimization of Bedside Chest X-rays Taken in the Intensive Care Unit by Using Current Software-based Techniques · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03561532 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Joint Authority for Päijät-Häme Social and Health Care
Last refreshed: 15 August 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03561532.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing